Gabriel Ghiaur
Has grant
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
The Role of Stromal CYP26 in Myelodysplastic Syndromes
Open Date: 2018-09-01
Close Date: 2020-08-01
Grant: Close
Bone Marrow Microenvironmental Expression of Cytochrome P450 Enzymes
Open Date: 2015-04-01
Close Date: 2020-03-01
Articles (7)
Background Melanoma is the deadliest form of skin cancer, with increasing incidence rates among the older population. The immune system experiences age‐related changes that can impact tumor progression and treatment efficacy. Additionally, aging leads to systemic non‐immune changes, such as enhanced adiposity and iron accumulation in the bone marrow (BM). Aims This study aims to investigate how age‐related alterations in the BM, alongside the presence of melanoma, influence the immune response and susceptibility to ferroptosis in aged mice. Methods and Results Utilizing an aged mouse model with melanoma, we observed significant changes in iron and lipid levels within the BM, as well as alterations in immune cell populations. Specifically, our findings indicate that tumor burden expands the myeloid compartment and contracts the lymphoid compartment in the BM niche. Aging increases neutral lipids within the BM, but tumor burden in aged mice appears to reverse this effect. We noted elevated intracellular neutral lipid levels in monocytes due to the tumor burden. Bone marrow–derived macrophages (BMDMs) from aged mice exhibited altered fatty acid synthase and fatty acid uptake protein expression. While aging leads to increased iron accumulation and lipid peroxidation in the BM, the presence of melanoma counteracts these changes. Disruptions in iron and lipid homeostasis heightened the risk of ferroptosis. Notably, imidazole ketone erastin and aging influenced intracellular ferrous iron levels and immune cell populations. Conclusion Overall, melanoma induces an age‐specific metabolic response in the BM, which may sensitize immune cells to ferroptosis inducers.
Year:
2026
Natural compounds are increasingly investigated for their potential as complementary therapies in hematologic malignancies. In this study, we examined ethanol extracts of turmeric (Curcuma longa) and ginger (Zingiber officinale) rhizomes, two phytocompounds with a long history of use in traditional medicine but limited evaluation as complex extracts in myeloid neoplasms. Phytochemical analysis revealed that turmeric extract contained a significantly higher concentration of total polyphenols compared to ginger, while GC–MS demonstrated distinct chemical profiles enriched in tumerones and curlone for turmeric and sesquiterpenes such as 7-epi-sesquithujene and β-sesquiphellandrene for ginger. Functional assays showed that both extracts reduced the viability of malignant myeloid blasts in a dose-dependent manner, with ginger demonstrating greater potency reflected by lower IC₅₀ values. Flow cytometry confirmed induction of apoptosis in leukemic cells, including in co-culture with mesenchymal stromal cells, suggesting the ability to overcome microenvironmental protection. At higher concentrations, both extracts also decreased the viability of normal CD34⁺ progenitors, although the effects were less pronounced at lower doses, indicating a degree of selectivity compared to malignant myeloid cell. Taken together, these results highlight the distinct and context-dependent biological activities of turmeric and ginger extracts, their potential to disrupt stromal support for malignant myeloid cells, and their relative sparing of normal hematopoietic progenitors at lower concentrations. These findings provide a rationale for further preclinical exploration of standardized extracts as complementary strategies in myeloid malignancies.
Year:
2025
A hallmark of cancer biology is resistance to apoptosis. BCL-2 is an anti-apoptotic molecule that is being overexpressed in several myeloid diseases, such as acute myeloid leukemia and myelodysplastic syndromes, but also in several lymphoid cancers, such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphomas and multiple myeloma. Venetoclax (VEN) is a BCL-2 small molecule inhibitor. Data about its structure, biochemical characteristics and in vitro efficacy against several blood cancer cell lines were first reported in 2013. Shortly after, the first clinical trials reported that single-agent VEN provides no long-term survival benefits. In contrast, when used in combination, VEN led to significantly improved outcomes and eventually to its first US FDA approvals in 2018. As the modern approach to treating hematological malignancies are the chemotherapy-free regimen, in the current manuscript, we provide a comprehensive view on all available therapies that are considered to be chemotherapy-free, with a special emphasis on acute myeloid leukemia (AML), where phase I-III clinical trials have provided the most data.
Year:
2025
Serine metabolism is of growing biologic and therapeutic interest in cancer. Upregulation of the serine synthesis pathway (SSP) can fuel tumor growth, and cancers with this phenotype are often sensitive to SSP inhibitors. In parallel, dietary restriction of serine and glycine (SG) can suppress some cancers, but the determinants of sensitivity to this approach are poorly understood. This is especially true in acute myeloid leukemia (AML), where serine metabolism has been less explored. We report that a subset of human AML cell lines and primary samples are completely dependent on external serine, known as serine auxotrophy. These leukemias consistently suppressed the SSP enzyme PSAT1, failed to synthesize serine, responded to SG restriction in vivo , and were rescued by restoring PSAT1. We also found that AML with an SF3B1 K700E mutation showed additional dependence on the SSP enzyme PHGDH, that SG restriction synergized with venetoclax in serine auxotrophic AML, and that MECOM rearrangement was strongly associated with PSAT1 suppression and serine auxotrophy. These findings define a metabolically distinct AML subtype and nominate it for targeting by SG restriction.
Year:
2025
Myelodysplastic syndromes (MDS) are myeloid malignancies with heterogeneous genotypes and phenotypes, characterized by ineffective haematopoiesis and a high risk of progression towards acute myeloid leukaemia (AML). Prognosis for patients treated with hypomethylating agents (HMAs), as is azacytidine, the main drug used as frontline therapy for MDS is mostly based on cytogenetics and next generation sequencing (NGS) of the initial myeloid clone. Although the critical influence of the epigenetic landscape upon cancer cells survival and development as well on tumour environment establishment is currently recognized and approached within current clinical practice in MDS, the heterogenous response of the patients to epigenetic therapy is suggesting a more complex mechanism of action, as is the case of RNA methylation. In this sense, the newly emerging field of epitranscriptomics could provide a more comprehensive perspective upon the modulation of gene expression in malignancies, as is the proof‐of‐concept of MDS. We initially did RNA methylation sequencing on MDS patients ( n = 6) treated with azacytidine and compared responders with non‐responders. Afterwards, the genes identified were assessed in vitro and afterwards validated on a larger cohort of MDS patients treated with azacytidine ( n = 58). Our data show that a more accurate prognosis could be based on analysing the methylome and thus we used methylation sequencing to differentially split high‐grade MDS patients with identical demographical and cytogenetic features, between azacytidine responders and non‐responders.
Year:
2024
Introduction: Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Current Treatment Paradigms and Lessons Learned from APL: Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve the outcomes of these challenging diseases. Does the BM Microenvironment Play a Role in MRD?: In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.
Year:
2024
Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Acute promyelocytic leukemia (APL) led the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve outcomes in these challenging diseases. In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.
Year:
2024
Collaborators (4)
William Dalton
Johns Hopkins University
Ashani Weeraratna
Department Chair, Bloomberg Professor
Johns Hopkins University Bloomberg School of Public Health
Carlo M. Croce
Distinguished University Professor
Ohio State University
Yash Chhabra
Assistant Professor
Fox Chase Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.